🇺🇸 FDA
Pipeline program

Vantictumab combined with paclitaxel

18R5-002

Phase 1 small_molecule completed

Quick answer

Vantictumab combined with paclitaxel for Metastatic Breast Cancer is a Phase 1 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Metastatic Breast Cancer
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials